Biologics in pediatric lung disease

McGhee, Sean

doi:10.1097/mop.0000000000000614

Cited by 3 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…además, reduce la expresión de receptores de Ige presentes sobre células presentadoras de antígeno, lo que disminuye la sensibilización alérgica. Diferentes metaanálisis demuestran que omalizumab es seguro en niños, reduce el riesgo de crisis de asma, consultas a servicios de urgencia y hospitalizaciones, permitiendo que los pacientes puedan incluso bajar el nivel del tratamiento controlador y mejorar significativamente su calidad de vida 41,52 . Cuando el tratamiento es exitoso los pacientes logran retomar las actividades deportivas y de la vida diaria que habían suspendido por la gravedad de la enfermedad 53 .…”

Section: Omalizumabunclassified

“…la acción de mepolizumab se ve reflejada en un menor recuento de eosinófilos en sangre y esputo y en una disminución significativa de las crisis de asma, de las hospitalizaciones y de las consultas a servicios de urgencia, con una mejoría asociada de la calidad de vida 41 . Su uso está indicado en pacientes con asma grave resistente a tratamiento con recuento de eosinófilos actual mayor a 150 células/ml o histórico mayor de 300 células/ml 41,52 . es muy importante recalcar que mepolizumab ha demostrado ser eficaz principalmente en el asma eosinofílico no alérgico del adulto.…”

Section: Mepolizumabunclassified

See 1 more Smart Citation

Consenso chileno SOCHINEP-SER para el diagnóstico y tratamiento del asma en el escolar

et al. 2020

Rev. chil. enferm. respir.

View full text Add to dashboard Cite

Chilean SoCHinEP-SER consensus for asthma diagnosis and treatment in school age children Bronchial asthma is the most prevalent chronic condition among children, however, in Chile, it is underdiagnosed. This may be due to medical professionals failing to recognize the disease. It is essential to be aware of the symptoms and signs that are suggestive of the disease in order to begin an appropriate treatment to achieve disease control. Asthma must be suspected in school age children who present repeated episodes of bronchial obstruction. The diagnosis should be confirmed with lung function tests that demonstrate variable airflow obstruction with a positive bronchodilator response. Treatment is based on two fundamental pillars: education and pharmacological treatment. Educational activities must include: information about the disease and its treatment, regular monitoring of treatment adherence, teaching and reviewing the correct inhalation technique at every checkup, developing a personalized written action plan and scheduling regular follow-up appointments. The gold standard for treatment is maintenance inhaled corticosteroids, in the lowest possible dose that enables disease control. The goal of the treatment is to eliminate daily symptoms and asthma crisis. Therapy should be increased if control is not achieved, but before starting it, adherence to maintenance treatment, inhalation technique, presence of associated comorbidities and environmental exposure should be evaluated. In the mild patient, who is not receiving maintenance therapy, rescue treatment should be done with bronchodilators, always associated with inhaled corticosteroids. This consensus is a guide to improve the diagnosis, treatment and control of asthma in schoolchildren

show abstract

Section: Omalizumabunclassified

Section: Mepolizumabunclassified

Consenso chileno SOCHINEP-SER para el diagnóstico y tratamiento del asma en el escolar

et al. 2020

Rev. chil. enferm. respir.

View full text Add to dashboard Cite

show abstract

The Potential for Phospholipids in the Treatment of Airway Inflammation: An Unexplored Solution

Komalla

Mehta

Achi

et al. 2021

CMP

View full text Add to dashboard Cite

: Asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF) are major inflammatory respiratory diseases. Current mainstay therapy for asthma, and chronic obstructive pulmonary disease are corticosteroids, which have well-established side effect profiles. Phospholipids (PLs) are ubiquitous, diverse compounds with varying functions such as their structural role incell membrane, energy storage, and cell signaling.Recent advances in understanding PLs role as inflammatory mediators in the body as well as their widespread long-standing use as carrier molecules in drug delivery demonstrate the potential application of phospholipids in modulating inflammatory conditions. This review briefly explains the main mechanisms of inflammation in chronic respiratory diseases, currentanti-inflammatory treatments and areas of unmet need. The structural features, roles of endogenous and exogenous phospholipids, including their use as pharmaceutical excipients are reviewed. Current research on the immunomodulatory properties of PLs and their potentialapplication in inflammatory diseasesis the major section of this review. Considering the roles of PLs as inflammatory mediators and their safety profile established in pharmaceutical formulations, these small molecules demonstrate great potential as candidates in respiratory inflammation. Future studies need to focus on the immunomodulatory properties and the underlying mechanisms of phospholipids in respiratory inflammatory diseases.

show abstract

The Role of Biologics in the Management of Asthma in the Pediatric Patient

Morris¹,

Autry²,

Kuhn³

2021

The Journal of Pediatric Pharmacology and Therapeutics

View full text Add to dashboard Cite

The management of pediatric patients with asthma continues to be a major health issue. For many patients, traditional therapies have been very effective, but for a large number of patients asthma remains poorly controlled. This leads to significant morbidity and impairment to quality of life. Recently, several new biologics, as well as new dosage forms of combination inhaled drugs, have been made available for use adding to the armamentarium of therapy for specific asthma phenotypes. Biologics have shown promise in the more difficult to manage asthma patient. Approved in children, omalizumab, an anti–immunoglobulin E (anti-IgE) antibody, has been available for several years. New agents, like mepolizumab and benralizumab, directed against interleukin (IL) 5, have indications for children >6 and >12 years of age, respectively. Dupilumab, an IL-4– and IL-13–directed antibody, has been studied as well in eosinophilic asthma, with positive results. A thorough understanding of the clinical data of these agents is key, as they may greatly improve the quality of life in children with difficult-to-manage asthma.

show abstract

Biologics in pediatric lung disease

Cited by 3 publications

References 47 publications

Consenso chileno SOCHINEP-SER para el diagnóstico y tratamiento del asma en el escolar

Consenso chileno SOCHINEP-SER para el diagnóstico y tratamiento del asma en el escolar

The Potential for Phospholipids in the Treatment of Airway Inflammation: An Unexplored Solution

The Role of Biologics in the Management of Asthma in the Pediatric Patient

Contact Info

Product

Resources

About